BACKGROUND. Central nervous system involvement is a common manifestation of non-Hodgkin lymphoma (NHL) in human immunodeficiency virus (HIV)-infected individuals. The purpose of this study was to review the frequency and pattern of neurologic manifestation of lymphoma in a cohort of HIV-infected ind
Determinants of antepartum human immunodeficiency virus testing in a non-Medicaid obstetric population
β Scribed by E. Cardonick; S. Daly; M. Dooley; K. Elles; N.S. Silverman
- Publisher
- Hindawi Publishing Corporation
- Year
- 1998
- Tongue
- English
- Weight
- 151 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1064-7449
No coin nor oath required. For personal study only.
β¦ Synopsis
Objective: To determine voluntary human immunodeficiency virus (HIV) testing rates and factors influencing testing in a private obstetric practice.
Methods: Antepartum patients were offered HIV testing after completing a self-assessment questionnaire. Perceived risks and demographics were correlated with testing rates.
Results: Overall, 348/600 (58%) women consented to HIV testing. In a univariate analysis, patients with ''any'' perceived risk(s) were more likely to be tested. Single women and those with an at-risk partner(s) or a history of sexually transmitted disease (STD) were more likely to desire testing. These factors remained independently associated with voluntary testing in a multivariate regression model. No patients tested positive for HIV.
Conclusions: In our private obstetric practice, 26% of women perceived themselves at risk for HIV infection, and testing rates depended on the various risks identified. A history of STDs or an at-risk sexual partner were stronger predictors of voluntary testing than was marital status. Focused HIV counseling among pregnant women at relatively low risk for infection may be possible.
π SIMILAR VOLUMES
## BACKGROUND. There is very little experience reported in the literature on the treatment of patients with relapsed or resistant human immunodeficiency virus-related non-Hodgkin's lymphoma (HIV-NIIL). We performed a prospective study to ovaluate the feasibility and activity of a second-line chemo